-
Update on products in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...
-
Hemlibra approved for all those with severe hemophilia A in Quebec – Access starts April 1
by David Page, CHS National Director of Health Policy March 1, 2022, Montréal – The Canadian Hemophilia Society (CHS) was informed yesterday by Héma-Québec that access...
-
Update on access to coagulation products for hemophilia A and B
by David Page, CHS National Director of Health Policy Access to a wide range of coagulation products is expanding in the provinces and territories served by...
-
Has the bleeding disorder world fundamentally changed?
by David Page, CHS National Director of Health Policy Given recent advances in therapies for inherited bleeding disorders, especially hemophilia A and B, I have...
-
Emicizumab rollout well underway
Montreal, December 16, 2021 – The rollout of emicizumab (Hemlibra) in the provinces and territories served by Canadian Blood Services (CBS) is well underway. Emicizumab...